Hailong Li
- Toxicology top 10%
-
- Pharmaceutical Practices and Patient Outcomes 3
-
- Toxoplasma gondii Research Studies 4
-
- Pharmaceutical studies and practices 8
-
- Pharmaceutical Economics and Policy 6
- Health Systems, Economic Evaluations, Quality of Life 4
-
- Acute Kidney Injury Research 4
-
- Antibiotics Pharmacokinetics and Efficacy 4
-
- Lipoproteins and Cardiovascular Health 3
- Partner nations
- ChinaUnited KingdomUnited States
In The Last Decade
Hailong Li
42 papers receiving 378 citations
Peers
Comparison fields: 5 of 116
- Toxicology 30
- Geriatrics and Gerontology 16
- Applied Microbiology and Biotechnology 8
- Parasitology 25
- Developmental Neuroscience 15
Countries citing papers authored by Hailong Li
This map shows the geographic impact of Hailong Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hailong Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hailong Li more than expected).
Fields of papers citing papers by Hailong Li
This network shows the impact of papers produced by Hailong Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hailong Li. The network helps show where Hailong Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hailong Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 2 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 5 | |
| 4 | 2023 | 0 | |
| 5 | 2023 | 10 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 4 | |
| 8 | 2023 | 14 | |
| 9 | 2022 | 3 | |
| 10 | 2022 | 18 | |
| 11 | 2022 | 5 | |
| 12 | 2022 | 1 | |
| 13 | 2022 | 10 | |
| 14 | 2020 | 1 | |
| 15 | 2019 | 4 | |
| 16 | 2019 | 24 | |
| 17 | 2016 | 17 | |
| 18 | 2015 | 33 | |
| 19 | 2008 | 21 | |
| 20 | Efficiency of the combined treatement with multiple antibiotics for Yersinia pestis infection in experimental rabbits | 2007 | 1 |
About Hailong Li
Hailong Li is a scholar working on Applied Microbiology and Biotechnology, Toxicology and Geriatrics and Gerontology, having authored 48 papers that have together received 389 indexed citations. Recurring topics across this work include Pharmaceutical studies and practices (8 papers), Pharmaceutical Economics and Policy (6 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers), Toxoplasma gondii Research Studies (4 papers), Acute Kidney Injury Research (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers), Lipoproteins and Cardiovascular Health (3 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). The work is most often cited by research in Toxicology (30 citations), Geriatrics and Gerontology (16 citations) and Applied Microbiology and Biotechnology (8 citations). Hailong Li has collaborated with scholars based in China, United Kingdom and United States. Frequent co-authors include Linan Zeng, Lingli Zhang, Chunsong Yang, Liang Huang, Bin Yi, Weixing Huang, Zhi‐Jun Jia, Caihong Shen, Guo Cheng and Zhe Chen. Their work appears in journals such as PLoS ONE, Scientific Reports and Polymer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.